Acceleron Pharma (XLRN) falls 0.29% on Moderate Volume September 14

Equities Staff  |

Acceleron Pharma Inc (NASDAQ: XLRN) shares fell 0.29%, or $0.39 per share, to close Tuesday at $132.19. After opening the day at $132.54, shares of Acceleron Pharma fluctuated between $133.75 and $131.50. 99,057 shares traded hands a decrease from their 30 day average of 198,501. Tuesday's activity brought Acceleron Pharma’s market cap to $8,050,439,871.

Acceleron Pharma is headquartered in Cambridge, Massachusetts..

About Acceleron Pharma Inc

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Visit Acceleron Pharma Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Acceleron Pharma Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Acceleron Pharma Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

President Biden's New Alliance With Australia and Britain Angers France and European Union
California Governor Newsom Signs Affordable Housing Law
COVID-19 Surge in Idaho Forcing Statewide Health Care Rationing
JPMorgan Launching Its First Overseas Digital Bank in United Kingdom Next Week
Federal Reserve Reviewing Ethics Policies in Wake of Prolific Trading Disclosed by Two Senior Officials
Chinese Property Developer Evergrande Not 'Too Big to Fail' — Global Times
August Retail Sales Rebound 0.7%, Surprising Economists After July Plunge
UN Report Shows COVID-19 Has Not Slowed Pace of Climate Change

Market Movers

Sponsored Financial Content